25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

B6E (Swedish Orphan Biovitrum AB (publ)) Stock Analysis
Buy, Hold or Sell?

Let's analyze Swedish Orphan Biovitrum AB (publ) together

I guess you are interested in Swedish Orphan Biovitrum AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Swedish Orphan Biovitrum AB (publ)’s Financial Insights
  • 📈 Technical Analysis (TA) – Swedish Orphan Biovitrum AB (publ)’s Price Targets

I'm going to help you getting a better view of Swedish Orphan Biovitrum AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Swedish Orphan Biovitrum AB (publ)

I send you an email if I find something interesting about Swedish Orphan Biovitrum AB (publ).

1. Quick Overview

1.1. Quick analysis of Swedish Orphan Biovitrum AB (publ) (30 sec.)










1.2. What can you expect buying and holding a share of Swedish Orphan Biovitrum AB (publ)? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€10.21
Expected worth in 1 year
€11.03
How sure are you?
91.2%

+ What do you gain per year?

Total Gains per Share
€0.82
Return On Investment
3.3%

For what price can you sell your share?

Current Price per Share
€24.56
Expected price per share
€21.06 - €29.40
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Swedish Orphan Biovitrum AB (publ) (5 min.)




Live pricePrice per Share (EOD)
€24.56
Intrinsic Value Per Share
€14.99 - €17.76
Total Value Per Share
€25.20 - €27.96

2.2. Growth of Swedish Orphan Biovitrum AB (publ) (5 min.)




Is Swedish Orphan Biovitrum AB (publ) growing?

Current yearPrevious yearGrowGrow %
How rich?$4b$3.4b$521.8m13.2%

How much money is Swedish Orphan Biovitrum AB (publ) making?

Current yearPrevious yearGrowGrow %
Making money$102.2m$55.2m$46.9m45.9%
Net Profit Margin14.4%8.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Swedish Orphan Biovitrum AB (publ) (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Swedish Orphan Biovitrum AB (publ)?

Welcome investor! Swedish Orphan Biovitrum AB (publ)'s management wants to use your money to grow the business. In return you get a share of Swedish Orphan Biovitrum AB (publ).

First you should know what it really means to hold a share of Swedish Orphan Biovitrum AB (publ). And how you can make/lose money.

Speculation

The Price per Share of Swedish Orphan Biovitrum AB (publ) is €24.56. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Swedish Orphan Biovitrum AB (publ).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Swedish Orphan Biovitrum AB (publ), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €10.21. Based on the TTM, the Book Value Change Per Share is €0.20 per quarter. Based on the YOY, the Book Value Change Per Share is €0.53 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Swedish Orphan Biovitrum AB (publ).

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.261.1%0.301.2%0.160.7%0.230.9%0.220.9%0.200.8%
Usd Book Value Change Per Share-0.38-1.5%0.241.0%0.612.5%0.381.6%0.311.2%0.351.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.38-1.5%0.241.0%0.612.5%0.381.6%0.311.2%0.351.4%
Usd Price Per Share30.08-30.95-24.25-26.11-24.11-21.61-
Price to Earnings Ratio28.59-43.14-80.91-53.78-48.16-43.34-
Price-to-Total Gains Ratio-79.53-77.92-4.18-56.59--30.01-23.69-
Price to Book Ratio2.56-2.70-2.43-2.70-2.96-4.54-
Price-to-Total Gains Ratio-79.53-77.92-4.18-56.59--30.01-23.69-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share28.239088
Number of shares35
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.240.31
Usd Total Gains Per Share0.240.31
Gains per Quarter (35 shares)8.2510.72
Gains per Year (35 shares)32.9942.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10332304333
20665608676
3099890129119
401321220172162
501651550214205
601981880257248
702312210300291
802642540343334
902972870386377
1003303200429420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%34.00.00.0100.0%34.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%17.03.00.085.0%31.03.00.091.2%31.03.00.091.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.034.00.0%0.00.034.00.0%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%17.03.00.085.0%31.03.00.091.2%31.03.00.091.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Swedish Orphan Biovitrum AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3290.205-261%0.528-162%0.333-199%0.266-223%0.300-210%
Book Value Per Share--10.2079.987+2%8.666+18%8.478+20%7.288+40%5.389+89%
Current Ratio--0.9790.915+7%0.692+42%0.815+20%0.845+16%1.074-9%
Debt To Asset Ratio--0.4430.475-7%0.558-21%0.509-13%0.526-16%0.504-12%
Debt To Equity Ratio--0.7960.907-12%1.282-38%1.058-25%1.126-29%1.050-24%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--6193585565.5206143015203.380+1%3487129061.280+78%4749583243.327+30%4450310075.244+39%4435424665.383+40%
Eps--0.2290.259-12%0.140+63%0.202+13%0.190+20%0.175+31%
Ev To Sales Ratio--2.6672.616+2%1.635+63%2.346+14%2.603+2%3.855-31%
Free Cash Flow Per Share--0.5970.348+72%0.151+295%0.176+240%0.183+225%0.199+200%
Free Cash Flow To Equity Per Share--0.5970.348+72%0.151+295%0.147+307%0.092+548%0.089+572%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--17.755----------
Intrinsic Value_10Y_min--14.992----------
Intrinsic Value_1Y_max--0.860----------
Intrinsic Value_1Y_min--0.844----------
Intrinsic Value_3Y_max--3.284----------
Intrinsic Value_3Y_min--3.121----------
Intrinsic Value_5Y_max--6.553----------
Intrinsic Value_5Y_min--6.022----------
Market Cap8435303723.520-7%8984838965.5209244145953.380-3%7243507961.280+24%7798906876.660+15%7201692275.244+25%6454435844.771+39%
Net Profit Margin--0.1350.144-6%0.085+59%0.128+6%0.140-4%0.171-21%
Operating Margin----0%-0%0.074-100%0.148-100%0.220-100%
Operating Ratio--1.0361.013+2%1.081-4%1.033+0%1.021+1%1.006+3%
Pb Ratio2.406-7%2.5632.698-5%2.433+5%2.701-5%2.964-14%4.542-44%
Pe Ratio26.838-7%28.58743.141-34%80.913-65%53.777-47%48.163-41%43.339-34%
Price Per Share24.560-7%26.16026.915-3%21.090+24%22.707+15%20.968+25%18.793+39%
Price To Free Cash Flow Ratio10.282-7%10.9522.070+429%10.944+0%23.052-52%19.210-43%11.519-5%
Price To Total Gains Ratio-74.669+6%-79.53377.915-202%4.183-2001%56.593-241%-30.010-62%23.694-436%
Quick Ratio--0.4290.370+16%0.286+50%0.378+14%0.410+5%0.482-11%
Return On Assets--0.0120.014-8%0.007+74%0.012+4%0.013-2%0.020-36%
Return On Equity--0.0220.026-13%0.016+42%0.024-6%0.027-16%0.038-42%
Total Gains Per Share---0.3290.205-261%0.528-162%0.333-199%0.266-223%0.300-210%
Usd Book Value--4030649885.4803944021423.920+2%3422211426.770+18%3348059253.377+20%2877975086.532+40%2128084974.175+89%
Usd Book Value Change Per Share---0.3780.236-261%0.607-162%0.383-199%0.306-223%0.345-210%
Usd Book Value Per Share--11.73611.483+2%9.964+18%9.748+20%8.379+40%6.196+89%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--7121384683.2357063238880.846+1%4009500994.660+78%5461070813.177+30%5116966524.516+39%5099851280.257+40%
Usd Eps--0.2630.298-12%0.161+63%0.232+13%0.219+20%0.201+31%
Usd Free Cash Flow--235827659.360137505904.270+72%59679679.120+295%69385370.880+240%72451956.468+225%48625637.191+385%
Usd Free Cash Flow Per Share--0.6870.400+72%0.174+295%0.202+240%0.211+225%0.229+200%
Usd Free Cash Flow To Equity Per Share--0.6870.400+72%0.174+295%0.169+307%0.106+548%0.102+572%
Usd Market Cap9698912221.303-7%10330767842.55510628919017.196-3%8328585453.880+24%8967183126.784+15%8280505778.076+25%7421310334.318+39%
Usd Price Per Share28.239-7%30.07930.947-3%24.249+24%26.109+15%24.109+25%21.608+39%
Usd Profit--90345535.000102219519.600-12%55291467.420+63%79710574.880+13%75105533.896+20%68934338.638+31%
Usd Revenue--667524438.600677255943.370-1%597313051.400+12%589233579.270+13%513968004.712+30%411137667.301+62%
Usd Total Gains Per Share---0.3780.236-261%0.607-162%0.383-199%0.306-223%0.345-210%
 EOD+5 -3MRQTTM+18 -17YOY+27 -83Y+27 -95Y+25 -1110Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of Swedish Orphan Biovitrum AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1526.838
Price to Book Ratio (EOD)Between0-12.406
Net Profit Margin (MRQ)Greater than00.135
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.429
Current Ratio (MRQ)Greater than10.979
Debt to Asset Ratio (MRQ)Less than10.443
Debt to Equity Ratio (MRQ)Less than10.796
Return on Equity (MRQ)Greater than0.150.022
Return on Assets (MRQ)Greater than0.050.012
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Swedish Orphan Biovitrum AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.380
Ma 20Greater thanMa 5026.945
Ma 50Greater thanMa 10026.386
Ma 100Greater thanMa 20026.983
OpenGreater thanClose25.260
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2025-06-14 12:53:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Swedish Orphan Biovitrum AB (publ) earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 13.5% means that €0.14 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 13.5%. The company is making a huge profit. +2
  • The TTM is 14.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ13.5%TTM14.4%-0.9%
TTM14.4%YOY8.5%+5.9%
TTM14.4%5Y14.0%+0.4%
5Y14.0%10Y17.1%-3.0%
4.3.1.2. Return on Assets

Shows how efficient Swedish Orphan Biovitrum AB (publ) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.2% Return on Assets means that Swedish Orphan Biovitrum AB (publ) generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 1.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.2%TTM1.4%-0.1%
TTM1.4%YOY0.7%+0.6%
TTM1.4%5Y1.3%+0.1%
5Y1.3%10Y2.0%-0.7%
4.3.1.3. Return on Equity

Shows how efficient Swedish Orphan Biovitrum AB (publ) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.2% Return on Equity means Swedish Orphan Biovitrum AB (publ) generated €0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 2.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.2%TTM2.6%-0.3%
TTM2.6%YOY1.6%+1.0%
TTM2.6%5Y2.7%-0.1%
5Y2.7%10Y3.8%-1.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Swedish Orphan Biovitrum AB (publ).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Swedish Orphan Biovitrum AB (publ) is operating .

  • Measures how much profit Swedish Orphan Biovitrum AB (publ) makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y14.8%-14.8%
5Y14.8%10Y22.0%-7.2%
4.3.2.2. Operating Ratio

Measures how efficient Swedish Orphan Biovitrum AB (publ) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.04 means that the operating costs are €1.04 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 1.036. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.013. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.036TTM1.013+0.023
TTM1.013YOY1.081-0.067
TTM1.0135Y1.021-0.008
5Y1.02110Y1.006+0.016
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Swedish Orphan Biovitrum AB (publ).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Swedish Orphan Biovitrum AB (publ) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.98 means the company has €0.98 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.979. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.915. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.979TTM0.915+0.064
TTM0.915YOY0.692+0.224
TTM0.9155Y0.845+0.070
5Y0.84510Y1.074-0.230
4.4.3.2. Quick Ratio

Measures if Swedish Orphan Biovitrum AB (publ) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.43 means the company can pay off €0.43 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.429. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.370. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.429TTM0.370+0.059
TTM0.370YOY0.286+0.084
TTM0.3705Y0.410-0.040
5Y0.41010Y0.482-0.072
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Swedish Orphan Biovitrum AB (publ).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Swedish Orphan Biovitrum AB (publ) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.44 means that Swedish Orphan Biovitrum AB (publ) assets are financed with 44.3% credit (debt) and the remaining percentage (100% - 44.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.443. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.475. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.443TTM0.475-0.031
TTM0.475YOY0.558-0.083
TTM0.4755Y0.526-0.051
5Y0.52610Y0.504+0.022
4.5.4.2. Debt to Equity Ratio

Measures if Swedish Orphan Biovitrum AB (publ) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 79.6% means that company has €0.80 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.796. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.907. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.796TTM0.907-0.111
TTM0.907YOY1.282-0.375
TTM0.9075Y1.126-0.219
5Y1.12610Y1.050+0.076
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Swedish Orphan Biovitrum AB (publ) generates.

  • Above 15 is considered overpriced but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 28.59 means the investor is paying €28.59 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The EOD is 26.838. Based on the earnings, the company is overpriced. -1
  • The MRQ is 28.587. Based on the earnings, the company is overpriced. -1
  • The TTM is 43.141. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD26.838MRQ28.587-1.748
MRQ28.587TTM43.141-14.554
TTM43.141YOY80.913-37.772
TTM43.1415Y48.163-5.022
5Y48.16310Y43.339+4.824
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The EOD is 10.282. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 10.952. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 2.070. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD10.282MRQ10.952-0.670
MRQ10.952TTM2.070+8.881
TTM2.070YOY10.944-8.874
TTM2.0705Y19.210-17.140
5Y19.21010Y11.519+7.691
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Swedish Orphan Biovitrum AB (publ) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.56 means the investor is paying €2.56 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The EOD is 2.406. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.563. Based on the equity, the company is underpriced. +1
  • The TTM is 2.698. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.406MRQ2.563-0.157
MRQ2.563TTM2.698-0.135
TTM2.698YOY2.433+0.265
TTM2.6985Y2.964-0.266
5Y2.96410Y4.542-1.578
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets70,120,000
Total Liabilities31,083,000
Total Stockholder Equity39,029,000
 As reported
Total Liabilities 31,083,000
Total Stockholder Equity+ 39,029,000
Total Assets = 70,120,000

Assets

Total Assets70,120,000
Total Current Assets11,715,000
Long-term Assets58,405,000
Total Current Assets
Cash And Cash Equivalents 997,000
Net Receivables 5,135,000
Inventory 3,884,000
Total Current Assets  (as reported)11,715,000
Total Current Assets  (calculated)10,016,000
+/- 1,699,000
Long-term Assets
Property Plant Equipment 1,577,000
Goodwill 9,639,000
Intangible Assets 45,717,000
Long-term Assets  (as reported)58,405,000
Long-term Assets  (calculated)56,933,000
+/- 1,472,000

Liabilities & Shareholders' Equity

Total Current Liabilities11,961,000
Long-term Liabilities19,122,000
Total Stockholder Equity39,029,000
Total Current Liabilities
Short Long Term Debt 3,909,000
Accounts payable 1,069,000
Other Current Liabilities 6,880,000
Total Current Liabilities  (as reported)11,961,000
Total Current Liabilities  (calculated)11,858,000
+/- 103,000
Long-term Liabilities
Long term Debt 9,746,000
Capital Lease Obligations Min Short Term Debt366,000
Long-term Liabilities Other 2,782,000
Long-term Liabilities  (as reported)19,122,000
Long-term Liabilities  (calculated)12,894,000
+/- 6,228,000
Total Stockholder Equity
Retained Earnings 22,799,000
Total Stockholder Equity (as reported)39,029,000
Total Stockholder Equity (calculated)22,799,000
+/- 16,230,000
Other
Capital Stock195,000
Common Stock Shares Outstanding 343,457
Net Debt 12,658,000
Net Invested Capital 52,684,000
Net Working Capital -246,000
Property Plant and Equipment Gross 1,577,000



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
9,974,139
10,332,000
10,682,000
11,075,000
10,902,907
11,386,000
12,124,000
16,266,000
17,183,157
29,973,000
30,170,000
32,794,000
45,658,000
46,430,000
42,642,000
44,134,000
48,283,000
48,192,000
46,197,000
46,733,000
48,661,000
48,809,000
48,429,000
50,933,000
52,496,000
53,911,000
75,783,000
75,571,000
74,027,000
74,518,000
73,168,000
72,195,000
75,444,000
70,120,000
70,120,00075,444,00072,195,00073,168,00074,518,00074,027,00075,571,00075,783,00053,911,00052,496,00050,933,00048,429,00048,809,00048,661,00046,733,00046,197,00048,192,00048,283,00044,134,00042,642,00046,430,00045,658,00032,794,00030,170,00029,973,00017,183,15716,266,00012,124,00011,386,00010,902,90711,075,00010,682,00010,332,0009,974,139
   > Total Current Assets 
2,911,253
3,304,000
3,769,000
4,263,000
4,157,070
4,710,000
5,558,000
5,662,000
6,601,908
5,351,000
5,624,000
5,466,000
7,323,000
7,479,000
5,102,000
5,462,000
8,168,000
7,969,000
6,689,000
7,392,000
8,778,000
9,363,000
8,044,000
8,099,000
11,210,000
10,299,000
10,817,000
11,026,000
12,671,000
12,107,000
11,546,000
12,647,000
13,162,000
11,715,000
11,715,00013,162,00012,647,00011,546,00012,107,00012,671,00011,026,00010,817,00010,299,00011,210,0008,099,0008,044,0009,363,0008,778,0007,392,0006,689,0007,969,0008,168,0005,462,0005,102,0007,479,0007,323,0005,466,0005,624,0005,351,0006,601,9085,662,0005,558,0004,710,0004,157,0704,263,0003,769,0003,304,0002,911,253
       Cash And Cash Equivalents 
785,790
1,032,000
1,189,000
1,758,000
1,478,496
1,750,000
2,306,000
2,488,000
2,998,742
463,000
1,189,000
1,077,000
737,000
842,000
213,000
164,000
404,000
633,000
233,000
212,000
1,045,000
1,063,000
360,000
288,000
1,361,000
198,000
790,000
678,000
904,000
527,000
779,000
594,000
1,140,000
997,000
997,0001,140,000594,000779,000527,000904,000678,000790,000198,0001,361,000288,000360,0001,063,0001,045,000212,000233,000633,000404,000164,000213,000842,000737,0001,077,0001,189,000463,0002,998,7422,488,0002,306,0001,750,0001,478,4961,758,0001,189,0001,032,000785,790
       Net Receivables 
1,130,310
1,284,000
1,457,000
1,410,000
1,523,433
1,897,000
2,067,000
1,999,000
2,165,163
3,443,000
2,267,000
1,983,000
4,625,000
4,881,000
2,743,000
2,756,000
4,525,000
4,259,000
3,154,000
3,966,000
4,105,000
4,935,000
4,260,000
4,503,000
6,518,000
6,439,000
4,417,000
4,226,000
5,169,000
5,575,000
4,812,000
4,675,000
5,195,000
5,135,000
5,135,0005,195,0004,675,0004,812,0005,575,0005,169,0004,226,0004,417,0006,439,0006,518,0004,503,0004,260,0004,935,0004,105,0003,966,0003,154,0004,259,0004,525,0002,756,0002,743,0004,881,0004,625,0001,983,0002,267,0003,443,0002,165,1631,999,0002,067,0001,897,0001,523,4331,410,0001,457,0001,284,0001,130,310
       Inventory 
870,046
988,000
1,123,000
1,095,000
1,053,268
1,064,000
1,185,000
1,174,000
1,284,112
1,445,000
1,482,000
1,623,000
1,772,000
1,755,000
2,146,000
2,542,000
3,053,000
3,076,000
3,302,000
3,215,000
3,424,000
3,365,000
3,424,000
3,308,000
3,332,000
3,662,000
4,073,000
3,928,000
3,874,000
3,564,000
3,731,000
3,994,000
4,159,000
3,884,000
3,884,0004,159,0003,994,0003,731,0003,564,0003,874,0003,928,0004,073,0003,662,0003,332,0003,308,0003,424,0003,365,0003,424,0003,215,0003,302,0003,076,0003,053,0002,542,0002,146,0001,755,0001,772,0001,623,0001,482,0001,445,0001,284,1121,174,0001,185,0001,064,0001,053,2681,095,0001,123,000988,000870,046
       Other Current Assets 
88
0
0
0
176
-1,000
0
1,000
172
0
0
0
1,000
1,000
0
0
2,000
1,000
0
-1,000
1,000
0
0
0
-1,000
0
0
-1,000
-2,000
0
-1,000
0
1,000
0
01,0000-1,0000-2,000-1,00000-1,0000001,000-1,00001,0002,000001,0001,0000001721,0000-1,00017600088
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
24,621,000
24,546,000
27,329,000
38,335,000
38,952,000
37,540,000
38,672,000
40,115,000
40,223,000
39,507,000
39,340,000
39,883,000
39,446,000
40,385,000
42,834,000
41,285,000
43,613,000
64,966,000
64,545,000
61,356,000
62,410,000
61,622,000
59,548,000
62,282,000
58,405,000
58,405,00062,282,00059,548,00061,622,00062,410,00061,356,00064,545,00064,966,00043,613,00041,285,00042,834,00040,385,00039,446,00039,883,00039,340,00039,507,00040,223,00040,115,00038,672,00037,540,00038,952,00038,335,00027,329,00024,546,00024,621,000000000000
       Property Plant Equipment 
121,023
126,000
126,000
122,000
134,182
133,000
135,000
135,000
136,299
539,000
488,000
508,000
518,000
514,000
594,000
564,000
534,000
516,000
491,000
481,000
493,000
380,000
360,000
309,000
274,000
270,000
307,000
264,000
251,000
257,000
253,000
384,000
1,584,000
1,577,000
1,577,0001,584,000384,000253,000257,000251,000264,000307,000270,000274,000309,000360,000380,000493,000481,000491,000516,000534,000564,000594,000514,000518,000508,000488,000539,000136,299135,000135,000133,000134,182122,000126,000126,000121,023
       Goodwill 
1,554,158
1,554,000
1,554,000
1,554,000
1,554,158
1,554,000
1,554,000
1,554,000
1,554,158
1,554,000
1,554,000
2,551,000
6,678,000
6,779,000
0
0
5,873,000
0
6,006,000
6,141,000
6,288,000
0
0
0
7,007,000
0
0
0
9,642,000
10,253,000
10,123,000
9,741,000
10,456,000
9,639,000
9,639,00010,456,0009,741,00010,123,00010,253,0009,642,0000007,007,0000006,288,0006,141,0006,006,00005,873,000006,779,0006,678,0002,551,0001,554,0001,554,0001,554,1581,554,0001,554,0001,554,0001,554,1581,554,0001,554,0001,554,0001,554,158
       Long Term Investments 
1,956
0
0
0
35,155
0
193,000
227,000
55,440
242,000
447,000
444,000
404,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000404,000444,000447,000242,00055,440227,000193,000035,1550001,956
       Intangible Assets 
5,251,852
5,193,000
5,089,000
4,981,000
4,890,913
4,789,000
4,686,000
8,688,000
8,422,578
22,286,000
22,057,000
23,826,000
30,736,000
31,239,000
36,361,000
0
32,918,000
0
32,271,000
32,040,000
32,135,000
0
39,112,000
0
33,006,000
0
63,673,000
0
50,478,000
50,880,000
50,102,000
48,137,000
48,515,000
45,717,000
45,717,00048,515,00048,137,00050,102,00050,880,00050,478,000063,673,000033,006,000039,112,000032,135,00032,040,00032,271,000032,918,000036,361,00031,239,00030,736,00023,826,00022,057,00022,286,0008,422,5788,688,0004,686,0004,789,0004,890,9134,981,0005,089,0005,193,0005,251,852
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
242,000
24,546,000
27,329,000
-2,000
1,000
1,000
0
-1,000
0
0
0
1,000
-1,000
1,000
0
0
0
1,000
0
0
0
32,000
202,000
0
0
00202,00032,0000001,0000001,000-1,0001,000000-1,00001,0001,000-2,00027,329,00024,546,000242,000000000000
> Total Liabilities 
4,619,861
4,740,000
4,715,000
4,723,000
4,202,383
4,171,000
4,273,000
7,767,000
8,143,060
15,492,000
15,198,000
17,108,000
28,728,000
27,776,000
24,020,000
25,350,000
28,077,000
27,328,000
25,023,000
24,990,000
25,458,000
25,052,000
24,103,000
25,868,000
25,971,000
26,083,000
47,408,000
41,138,000
40,160,000
38,616,000
36,817,000
35,086,000
35,149,000
31,083,000
31,083,00035,149,00035,086,00036,817,00038,616,00040,160,00041,138,00047,408,00026,083,00025,971,00025,868,00024,103,00025,052,00025,458,00024,990,00025,023,00027,328,00028,077,00025,350,00024,020,00027,776,00028,728,00017,108,00015,198,00015,492,0008,143,0607,767,0004,273,0004,171,0004,202,3834,723,0004,715,0004,740,0004,619,861
   > Total Current Liabilities 
1,758,094
2,022,000
2,192,000
2,341,000
2,364,818
2,491,000
2,780,000
6,550,000
6,951,070
7,603,000
7,517,000
4,161,000
5,741,000
5,764,000
5,283,000
7,004,000
10,443,000
10,330,000
7,952,000
7,910,000
8,761,000
9,056,000
7,882,000
9,173,000
14,857,000
14,713,000
18,387,000
13,671,000
19,095,000
17,105,000
15,892,000
13,901,000
12,600,000
11,961,000
11,961,00012,600,00013,901,00015,892,00017,105,00019,095,00013,671,00018,387,00014,713,00014,857,0009,173,0007,882,0009,056,0008,761,0007,910,0007,952,00010,330,00010,443,0007,004,0005,283,0005,764,0005,741,0004,161,0007,517,0007,603,0006,951,0706,550,0002,780,0002,491,0002,364,8182,341,0002,192,0002,022,0001,758,094
       Short-term Debt 
502,216
504,000
504,000
505,000
5,044
6,000
7,000
0
0
82,000
84,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000084,00082,000007,0006,0005,044505,000504,000504,000502,216
       Short Long Term Debt 
502,216
504,000
504,000
505,000
5,044
6,000
7,000
0
0
82,000
84,000
0
0
0
0
2,108,000
4,015,000
4,095,000
2,025,000
2,040,000
1,768,000
1,024,000
1,321,000
1,689,000
5,795,000
5,933,000
10,542,000
3,249,000
8,813,000
7,499,000
5,943,000
6,001,000
3,926,000
3,909,000
3,909,0003,926,0006,001,0005,943,0007,499,0008,813,0003,249,00010,542,0005,933,0005,795,0001,689,0001,321,0001,024,0001,768,0002,040,0002,025,0004,095,0004,015,0002,108,000000084,00082,000007,0006,0005,044505,000504,000504,000502,216
       Accounts payable 
280,173
0
0
0
358,449
0
0
0
486,972
743,000
419,000
347,000
681,000
487,000
456,000
414,000
569,000
392,000
434,000
795,000
558,000
545,000
519,000
361,000
1,252,000
625,000
933,000
1,055,000
1,024,000
671,000
1,055,000
1,366,000
944,000
1,069,000
1,069,000944,0001,366,0001,055,000671,0001,024,0001,055,000933,000625,0001,252,000361,000519,000545,000558,000795,000434,000392,000569,000414,000456,000487,000681,000347,000419,000743,000486,972000358,449000280,173
       Other Current Liabilities 
668,621
2,020,000
2,190,000
2,339,000
887,691
2,490,000
2,778,000
6,549,000
4,853,803
6,778,000
7,014,000
3,724,000
1,922,000
5,175,000
4,716,000
4,371,000
1,498,000
5,730,000
5,381,000
4,961,000
1,090,000
7,362,000
5,910,000
6,987,000
7,675,000
8,021,000
6,759,000
9,227,000
2,703,000
8,789,000
8,766,000
6,395,000
7,596,000
6,880,000
6,880,0007,596,0006,395,0008,766,0008,789,0002,703,0009,227,0006,759,0008,021,0007,675,0006,987,0005,910,0007,362,0001,090,0004,961,0005,381,0005,730,0001,498,0004,371,0004,716,0005,175,0001,922,0003,724,0007,014,0006,778,0004,853,8036,549,0002,778,0002,490,000887,6912,339,0002,190,0002,020,000668,621
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
7,889,000
7,681,000
12,947,000
22,987,000
22,012,000
18,737,000
18,346,000
17,634,000
16,998,000
17,071,000
17,080,000
16,697,000
15,996,000
16,221,000
16,695,000
11,114,000
11,370,000
29,021,000
27,467,000
21,065,000
21,511,000
20,925,000
21,185,000
22,549,000
19,122,000
19,122,00022,549,00021,185,00020,925,00021,511,00021,065,00027,467,00029,021,00011,370,00011,114,00016,695,00016,221,00015,996,00016,697,00017,080,00017,071,00016,998,00017,634,00018,346,00018,737,00022,012,00022,987,00012,947,0007,681,0007,889,000000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
396,000
381,000
386,000
419,000
406,000
476,000
447,000
419,000
402,000
380,000
374,000
361,000
389,000
411,000
361,000
334,000
328,000
359,000
311,000
316,000
318,000
289,000
393,000
402,000
366,000
366,000402,000393,000289,000318,000316,000311,000359,000328,000334,000361,000411,000389,000361,000374,000380,000402,000419,000447,000476,000406,000419,000386,000381,000396,000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
1,560,000
1,792,000
3,968,000
2,621,000
6,668,000
6,357,000
3,775,000
3,473,000
3,980,000
3,916,000
4,069,000
3,834,000
3,911,000
4,154,000
4,562,000
3,900,000
4,359,000
4,003,000
2,316,000
2,530,000
3,049,000
3,045,000
2,941,000
3,172,000
2,782,000
2,782,0003,172,0002,941,0003,045,0003,049,0002,530,0002,316,0004,003,0004,359,0003,900,0004,562,0004,154,0003,911,0003,834,0004,069,0003,916,0003,980,0003,473,0003,775,0006,357,0006,668,0002,621,0003,968,0001,792,0001,560,000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
181,940
0
0
0
492,000
0
0
0
546,000
0
0
0
517,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000517,000000546,000000492,000000181,94000000000
> Total Stockholder Equity
5,354,278
5,592,000
5,967,000
6,352,000
6,700,524
7,215,000
7,851,000
8,499,000
9,040,097
14,481,000
14,972,000
15,686,000
16,930,000
18,654,000
18,622,000
18,784,000
20,206,000
20,864,000
21,174,000
21,743,000
23,203,000
23,757,000
24,326,000
25,065,000
26,525,000
27,828,000
28,375,000
34,433,000
33,867,000
35,887,000
36,336,000
37,094,000
40,286,000
39,029,000
39,029,00040,286,00037,094,00036,336,00035,887,00033,867,00034,433,00028,375,00027,828,00026,525,00025,065,00024,326,00023,757,00023,203,00021,743,00021,174,00020,864,00020,206,00018,784,00018,622,00018,654,00016,930,00015,686,00014,972,00014,481,0009,040,0978,499,0007,851,0007,215,0006,700,5246,352,0005,967,0005,592,0005,354,278
   Common Stock
149,254
5,592,000
5,967,000
6,352,000
149,527
7,215,000
7,851,000
8,499,000
149,974
14,481,000
14,972,000
15,686,000
165,000
18,654,000
18,622,000
18,784,000
167,000
20,864,000
21,174,000
21,743,000
169,000
23,757,000
24,326,000
25,065,000
26,525,000
170,000
0
0
0
0
0
0
0
0
00000000170,00026,525,00025,065,00024,326,00023,757,000169,00021,743,00021,174,00020,864,000167,00018,784,00018,622,00018,654,000165,00015,686,00014,972,00014,481,000149,9748,499,0007,851,0007,215,000149,5276,352,0005,967,0005,592,000149,254
   Retained Earnings 
388,799
0
0
0
1,547,826
0
0
0
3,965,174
0
0
0
7,269,000
0
0
0
10,477,000
0
0
0
13,155,000
0
0
0
15,793,000
17,027,000
17,248,000
17,343,000
18,055,000
18,839,000
19,063,000
20,526,000
21,924,000
22,799,000
22,799,00021,924,00020,526,00019,063,00018,839,00018,055,00017,343,00017,248,00017,027,00015,793,00000013,155,00000010,477,0000007,269,0000003,965,1740001,547,826000388,799
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue26,027,000
Cost of Revenue-5,785,000
Gross Profit20,242,00020,242,000
 
Operating Income (+$)
Gross Profit20,242,000
Operating Expense-20,402,000
Operating Income5,625,000-160,000
 
Operating Expense (+$)
Research Development3,538,000
Selling General Administrative7,553,000
Selling And Marketing Expenses-
Operating Expense20,402,00011,091,000
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-1,219,000
Net Interest Income-1,219,000
 
Pretax Income (+$)
Operating Income5,625,000
Net Interest Income-1,219,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)4,407,0005,625,000
EBIT - interestExpense = 0
3,885,000
3,885,000
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-4,407,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax4,407,000
Tax Provision-528,000
Net Income From Continuing Ops3,879,0003,879,000
Net Income3,885,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,219,000
 

Technical Analysis of Swedish Orphan Biovitrum AB (publ)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Swedish Orphan Biovitrum AB (publ). The general trend of Swedish Orphan Biovitrum AB (publ) is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Swedish Orphan Biovitrum AB (publ)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Swedish Orphan Biovitrum AB (publ) Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Swedish Orphan Biovitrum AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 28.50 < 28.58 < 29.40.

The bearish price targets are: 22.40 > 21.54 > 21.06.

Know someone who trades $B6E? Share this with them.👇

Swedish Orphan Biovitrum AB (publ) Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Swedish Orphan Biovitrum AB (publ). The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Swedish Orphan Biovitrum AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Swedish Orphan Biovitrum AB (publ). The current macd is -0.40761184.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Swedish Orphan Biovitrum AB (publ) price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Swedish Orphan Biovitrum AB (publ). This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Swedish Orphan Biovitrum AB (publ) price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Swedish Orphan Biovitrum AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartSwedish Orphan Biovitrum AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Swedish Orphan Biovitrum AB (publ). The current adx is 16.07.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Swedish Orphan Biovitrum AB (publ) shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Swedish Orphan Biovitrum AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Swedish Orphan Biovitrum AB (publ). The current sar is 27.87.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Swedish Orphan Biovitrum AB (publ) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Swedish Orphan Biovitrum AB (publ). The current rsi is 28.38. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Swedish Orphan Biovitrum AB (publ) Daily Relative Strength Index (RSI) ChartSwedish Orphan Biovitrum AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Swedish Orphan Biovitrum AB (publ). The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Swedish Orphan Biovitrum AB (publ) price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Swedish Orphan Biovitrum AB (publ) Daily Stochastic Oscillator ChartSwedish Orphan Biovitrum AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Swedish Orphan Biovitrum AB (publ). The current cci is -214.53796351.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Swedish Orphan Biovitrum AB (publ) Daily Commodity Channel Index (CCI) ChartSwedish Orphan Biovitrum AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Swedish Orphan Biovitrum AB (publ). The current cmo is -62.68096724.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Swedish Orphan Biovitrum AB (publ) Daily Chande Momentum Oscillator (CMO) ChartSwedish Orphan Biovitrum AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Swedish Orphan Biovitrum AB (publ). The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Swedish Orphan Biovitrum AB (publ) Daily Williams %R ChartSwedish Orphan Biovitrum AB (publ) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Swedish Orphan Biovitrum AB (publ). The current atr is 0.50689753.

Swedish Orphan Biovitrum AB (publ) Daily Average True Range (ATR) ChartSwedish Orphan Biovitrum AB (publ) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Swedish Orphan Biovitrum AB (publ). The current obv is 6,568.

Swedish Orphan Biovitrum AB (publ) Daily On-Balance Volume (OBV) ChartSwedish Orphan Biovitrum AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Swedish Orphan Biovitrum AB (publ). The current mfi is 37.14.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Swedish Orphan Biovitrum AB (publ) Daily Money Flow Index (MFI) ChartSwedish Orphan Biovitrum AB (publ) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Swedish Orphan Biovitrum AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-29 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-05 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-28 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-06 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-31 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-23 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-30 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-12 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-13 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-27 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-30 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-12 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-19 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Swedish Orphan Biovitrum AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Swedish Orphan Biovitrum AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.380
Ma 20Greater thanMa 5026.945
Ma 50Greater thanMa 10026.386
Ma 100Greater thanMa 20026.983
OpenGreater thanClose25.260
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Swedish Orphan Biovitrum AB (publ) with someone you think should read this too:
  • Are you bullish or bearish on Swedish Orphan Biovitrum AB (publ)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Swedish Orphan Biovitrum AB (publ)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Swedish Orphan Biovitrum AB (publ)

I send you an email if I find something interesting about Swedish Orphan Biovitrum AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Swedish Orphan Biovitrum AB (publ).

Receive notifications about Swedish Orphan Biovitrum AB (publ) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.